Abstract:
The present invention provides compounds for treating or preventing an HIV infection, or treating AIDS or ARC comprising administering a compound according to formula (I) where Ar, R 1 -R 5 , R 11c and X 1 are as defined herein.
Abstract:
The invention relates to prodrugs of JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses prodrugs of JNK inhibitors, as described below in formula (I), wherein m, n, p, q, Q, r, R 1 , R 2 , R 3 , X, X 1 , X 2 , X 3 , X 4 , X 5 , Y 1 , Y 2 , Z 1 , and Z 2 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.
Abstract:
The invention is concerned with novel JNK modulator of formula (I) wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , R, R 1 , Z and n are as defined in the description and the claims, as well as physiologically acceptable salts thereof.
Abstract:
The invention is concerned with novel JNK modulator of formula (I) wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , R, R 1 , Z and n are as defined in the description and the claims, as well as physiologically acceptable salts thereof.
Abstract:
The present invention relates to a compounds according to formula (I), methods for treating diseases mediated by human immunodeficieny virus by administration of a compound according to formula (I) and pharmaceutical compositions for treating diseases mediated by human immunodeficieny virus containing a compound according to formula where R 1 , R 2 , R 3 , R 4 , R 5 , are as defined herein.
Abstract:
The present invention relates to a compounds according to formula (I), methods for treating diseases mediated by human immunodeficieny virus by administration of a compound according to formula (I) and pharmaceutical compositions for treating diseases mediated by human immunodeficieny virus containing a compound according to formula (I) where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.
Abstract:
This invention relates to novel pyrazole derivatives of formula (I) wherein R1 to R4 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibits or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula (I) and pharmaceutical compositions of formula (I) admixed with at least one solvent, carrier or excipient. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated (formula I).
Abstract:
The present invention relates to compounds of formula (I), wherein R4, R5, R6, R7, Q, m and n are as defined in the specification. The compounds are useful as p38 kinase inhibitors, and therefore, may be used for treatment of p38-mediated disorder.
Abstract:
The present invention relates to compounds of formula (I), wherein R4, R5, R6, R7, Q, m and n are as defined in the specification. The compounds are useful as p38 kinase inhibitors, and therefore, may be used for treatment of p38-mediated disorder.